An observational study in Femoropopliteal In-Stent Restenosis (ISR), sponsored by Chunshui He. Not yet recruiting at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Chunshui He · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Peripheral Arterial Disease with a site in China — 32 open to participants now, 34 under way, 4 of them phase 3. Peripheral Arterial Disease · China.
Among the 80 studies in Peripheral Arterial Disease with a site in China, this one is the 6th largest by planned enrollment of the 27 observational ones that give a count, is the only one that started in 2027, is one of 27 observational ones, reaches primary completion later than 33 of the 33 other live ones, and was the 73rd registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →32 of the 80 studies in Peripheral Arterial Disease with a site in China are open now. Recruiting first, the newest first:
Peking University First Hospital · Sites in China
Ages 18–100 · Healthy volunteers
Eli Lilly and Company · Sites in China, United States, Argentina and 15 more countries
Ages 18+
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18+
Sirius Therapeutics Co., Ltd. · Sites in China
Ages 18–75
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 11 · Phase 4 1
First in 2008; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 187 across 399 observational studies indexed under Peripheral Arterial Disease.
Median enrollment 167 across the 53 interventional studies, 254 across the 27 observational. Of the 25 that completed or were terminated, 5 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 80 have an industry lead sponsor. The 10 most frequent:
Chunshui He is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Chunshui He has 1 study filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
10 of the studies in Peripheral Arterial Disease with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06539689FrontAce Scientific Co., LtdA Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries | 2026-12-04 |
| NCT07397390The First Affiliated Hospital of Dalian Medical Universityan Observational Study Evaluting the Effectiveness and Safety of DKutting LL Noval Scoring Balloon Angioplasty for Vessel Preparation Facilitated by IVUS on the Lower Limb Ischemia Patients With Calcified Lesions | 2026-12-30 |
| NCT07602634Zhijun BaoRadiomics Features Predicting Outcomes of PAD | 2026-12-31 |
| NCT03791970Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityStents Post-dilation With DCB or POBA in Femoropopliteal Arteries | 2026-12-31 |
| NCT07860138Fudan UniversityHemodynamic Characteristics of Peripheral Arterial Disease Using Computational Fluid Dynamics | 2027-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 80 studies in Peripheral Arterial Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Femoropopliteal in-stent restenosis (ISR) remains an important cause of recurrent symptoms and repeat revascularization after lower-extremity endovascular treatment. Drug-coated balloons (DCBs) avoid an additional permanent metallic layer, whereas drug-eluting stents provide mechanical scaffolding with local antiproliferative drug delivery. Direct prospective comparative-effectiveness evidence in symptomatic femoropopliteal ISR remains limited.
DEFIER is a prospective, multicenter observational comparative-effectiveness cohort study enrolling up to 600 adults with symptomatic Rutherford category 2-5 femoropopliteal ISR. Treatment is selected by the treating physician as part of routine clinical care and is not assigned by the research protocol. After guidewire crossing and lesion preparation, patients for whom both strategies remain clinically feasible enter the primary comparative cohort. The DCB-first strategy uses IN.PACT Admiral or AcoArt Orchid 0.035, with protocol-defined focal bare-metal bailout stenting permitted when clinically required. The Eluvia-first strategy uses the Eluvia drug-eluting vascular stent.
Participants will be followed for 24 months. The primary outcome is the cumulative incidence of first clinically driven target lesion revascularization (CD-TLR) through 24 months. Comparative analyses will use a prespecified target-trial framework and propensity-score overlap weighting, with death and major target-limb amputation treated as competing events.
Adults with symptomatic Rutherford category 2-5 femoropopliteal in-stent restenosis undergoing clinically indicated endovascular treatment at participating tertiary vascular centers in China. Potentially eligible patients will be screened consecutively. Treatment is selected by the treating physician as part of routine clinical care and is not assigned by the research protocol. The primary comparative cohort includes patients for whom both DCB-first and Eluvia-first strategies remain clinically feasible after lesion preparation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age >18 years. Willing and able to provide written . Rutherford Clinical Category 2-5. Angiographically confirmed ≥50% stenosis or occlusion within a previously implanted superficial femoral or proximal popliteal artery stent more than 30 days after implantation.
The target lesion is within the previously stented segment or extends no more than 3 cm proximally or distally beyond the prior stent.
Total target lesion length ≤30 cm. At least one patent below-the-knee runoff vessel. Willing and able to complete follow-up through 24 months. After lesion preparation, both the DCB-first and Eluvia-first strategies remain clinically feasible.
Exclusion Criteria:
Pregnancy or lactation. Rutherford Clinical Category 0 or 6. Target lesion stenosis \<50%. Target lesion length >30 cm. Severe calcification precluding endovascular treatment. Acute limb ischemia or acute thrombosis of the target limb. Untreated hemodynamically significant aorto-iliac inflow disease. Cerebrovascular accident within 60 days before the index procedure. to required antiplatelet or anticoagulant therapy. Inability or unwillingness to provide . \<2 years or another factor making completion of follow-up unlikely.
Persistent post-preparation anatomy that mandates one treatment strategy and therefore eliminates clinical equipoise.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants whose treating physician selects a drug-coated balloon-first strategy as part of routine clinical care after lesion preparation and confirmation that both treatment strategies remain clinically feasible. The prespecified DCB platforms are IN.PACT Admiral and AcoArt Orchid 0.035. Protocol-defined focal bare-metal bailout stenting is permitted when clinically necessary. Treatment is not assigned by the research protocol.
Device: Drug-Coated Balloon-First Strategy
Participants whose treating physician selects an Eluvia-first strategy as part of routine clinical care after lesion preparation and confirmation that both treatment strategies remain clinically feasible. The strategy uses the Eluvia Drug-Eluting Vascular Stent System. Treatment is not assigned by the research protocol.
Device: Eluvia Drug-Eluting Stent-First Strategy
Physician-selected routine-care treatment with either IN.PACT Admiral or AcoArt Orchid 0.035 after lesion preparation. Device size and length are selected according to vessel anatomy and locally approved instructions for use. Protocol-defined focal bare-metal bailout stenting is permitted when clinically required for a suboptimal DCB result.
Physician-selected routine-care treatment with the Eluvia Drug-Eluting Vascular Stent System after lesion preparation. Stent diameter and length are selected according to vessel anatomy and locally approved instructions for use.
Clinically-Driven Target Lesion Revascularization (CD-TLR)
Clinically driven target lesion revascularization (CD-TLR) is defined as repeat percutaneous or surgical revascularization of the target lesion, defined as the treated segment plus 5 mm proximally and distally, for ≥50% restenosis or occlusion accompanied by recurrent or worsening limb symptoms, Rutherford-category deterioration, ABI/TBI decline consistent with hemodynamic worsening, including an ABI decline ≥0.15 from the post-procedure reference when applicable, or failure or worsening of tissue loss in patients with chronic limb-threatening ischemia. Events will be independently adjudicated.
Time frame: 24 months post-procedure
First Clinically Driven Target Lesion Revascularization Through 12 Months
Number and percentage of participants experiencing first clinically driven target lesion revascularization within 12 months after time zero, using the same prespecified clinical and anatomical definition and independent adjudication procedures as the 24-month primary outcome.
Time frame: From post-preparation time zero through 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Dec 2030, 47 months later.
Of 138 non-industry observational studies under Peripheral Arterial Disease, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 116. This study's planned 47 months is above that.
Counting every sponsor, half of 196 studies reached it within 36 months; a quarter within 22 and three quarters within 73.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Jan 2029 → Dec 2030 and completion Jan 2029 → Dec 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chunshui He